Lyon, France and Yardley, PA —06 January 2015 – Mapi Group completes the acquisition of select Life Sciences services.
Mapi, a leading Health Research and Commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams.
“Today’s therapeutics market is driven by patient outcomes and treatment value proven by real-world evidence. This acquisition enables Mapi to strengthen our industry-leading expertise and integrated solutions to help our clients accelerate market adoption of their novel therapeutics,” said James Karis, Mapi’s Chief Executive Officer. “Mapi is an industry leader in Patient Reported Outcomes research and delivers global proficiency in Health Economics, unparalleled depth of experience in Health Research and global expertise in the commercialization of novel therapeutics. With this acquisition, we are also the largest independent company exclusively dedicated to Health Research and Commercialization services.”
With the addition of these new services and experts, Mapi expands its team of hundreds of indirect research experts covering the Americas, Europe, and Asia Pacific with additional expertise in Strategic Regulatory Services, Epidemiology, Strategic Market Access, Health Economics Outcomes Research, Patient Centered Outcomes, Language Services, Patient Insights, Direct to Patient Support and Real-World Evidence. To learn more about Mapi’s capabilities, visit www.mapigroup.com.
Mapi Group has over 40 years of experience supporting Life-Science companies in utilizing Patient Reported Outcomes measures, Value communications and Commercialization support, Strategic Regulatory Services, and gathering Real-World Evidence on Pharmaceuticals, Biologicals, and Medical devices. Mapi Group is the premier provider of Health Research and Commercialization services to Life-Science companies enabling Market Authorization, Market Access and Market Adoption of novel therapeutics. Visit http://www.mapigroup.com for more information.
Press contact: Media@mapigroup.com